Back this week to update you on the data for hydroxychlorquine.  There has been a lot of action - and very little resolution - to this issue since my last episode.  Let me know what you think, follow along on twitter @ebrheum and get the papers themselves at ebrheum.com.  

Diving into a new "rheum treatments for COVID" topic today - IL6 inhibition. It took me awhile to get to this, in part because the hydroxychloroquine situation has been something to behold and in part because there's just nothing to say. I cover two case series here, neither of which are strong evidence. Hope you enjoy! Follow me @ebrheum to let me know what you think! 

Trying to get to IL6, but so much happening in the world of hydroxychloroquine. As I said at the beginning, things are likely to move fast.  I'm planning to make this as an extended series, so please go back and listen to #1 before you listen to this!  This episode will round out the paper by Gautret et al. and discuss the best copy of a paper by Jun et al. that I've been able to find. Follow me @ebrheum and share with friends! 

Welcome to the first episode of my series on immunosuppressive treatments for COVID-19. Today I cover the Renault trial and a nice systematic review, which I believe are the two best options in the published literature to date.  Find the papers and ways to subscribe at ebrheum.com and follow me on twitter @ebrheum

Quick update podcast.  I'm planning to tweak the format of my podcast to better respond to COVID-19.  I'll be doing more or less the same thing but with a different structure and focus.  It seems a little peculiar to discuss anything else during the current crisis, so I intend to refocus and hope to offer value to listeners.  Share with friends - ebrheum.com and @ebrheum

PEXIVAS has landed!  This week I go over the trial and my take on it's results.  Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum! 

(Yet) another RCT this week!  Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a separate common problem in trials! 

This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE.  Great to see a new drug in this disease state; interesting to think through how these trials played out.  Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback! 

Happy New Year!  This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line."  Please be sure to VOTE AGAIN on twitter (@ebrheum) after you have listened! 

This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD.  The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/